BioCentury
ARTICLE | Product Development

Leaving cancer behind, Agios preps submission after latest readout in rare anemia

January 27, 2021 2:05 AM UTC

With its oncology business in the rear view mirror, Agios is readying its first non-cancer candidate for a regulatory submission with more data in a rare anemia.

After the bell Tuesday, Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said mitapivat met the primary endpoint in a second Phase III trial, ACTIVATE-T, to treat pyruvate kinase deficiency in patients who are regularly transfused...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.